Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIDENT-1 repotrectinib study in ROS1- or NTRK-rearranged advanced solid tumors
2024-512606-25-00Phase 2Authorised
- Sponsor
- Turning Point Therapeutics, Inc.
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 18
01
Overview
Phase 2, open-label trial of repotrectinib in Nonhematologic neoplasms and non-small cell lung cancer (NSCLC) (6 arms), sponsored by Turning Point Therapeutics, Inc. Primary endpoint: Objective Response Rate. Planned start Jul 2024; status: authorised.
02
Drugs
repotrectinib
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-512606-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512606-25-00.